Business Context and Reporting Period
This Form 8-K Current Report was filed by DaVita Inc. on May 25, 2022. The filing discloses a strategic agreement entered into on the same date with Medtronic, Inc. to form a new, independent kidney care-focused medical device company ("NewCo").
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed joint venture rather than DaVita's historical operating results. Key financial terms include:
- Equity Structure: DaVita and Medtronic will hold equal equity stakes in NewCo.
- Initial Cash Contributions: Each party will contribute approximately $200 million in cash at closing.
- DaVita's Upfront Payment: DaVita will pay Medtronic approximately $75 million in cash, subject to adjustments.
- Non-Cash Contributions: DaVita will contribute non-cash assets valued at approximately $25 million.
- Contingent Consideration: DaVita agreed to pay up to an additional $300 million if specific regulatory and commercial milestones are met between 2024 and 2028.
- Accounting Impact: DaVita expects to report its share of NewCo's operating income/loss under "Other (loss) income, net."
Material Changes and Anticipated Financial Impact
While this filing does not report changes to DaVita's historical revenue or profit, it outlines anticipated future financial impacts:
- Quarterly Charges: If the transaction closes in 2023, DaVita anticipates quarterly charges of approximately $20 million following closing.
- Break-Even Timeline: These charges are expected to decrease over time, reaching $0 approximately two to three years after closing when NewCo is projected to achieve break-even operating income.
- Long-Term Outlook: Management states the transaction is not expected to impact the Company's long-term outlook announced at its Capital Markets Day on November 16, 2021.
Guidance, Risks, and Contingencies
The filing contains significant forward-looking statements and identifies several risks and contingencies:
- Closing Conditions: The transaction is expected to close in 2023, subject to customary closing conditions and regulatory approvals, including the Hart-Scott-Rodino Act.
- Operational Risks: Risks include the ability to successfully separate NewCo from Medtronic, manage a joint venture, and retain appropriate staff.
- Capital Allocation: There is a risk regarding the use of capital for NewCo versus alternative purposes, such as stock repurchases.
- Asset Impairment: Potential impairment of goodwill, investments, or other assets is noted as a risk.
- Forward-Looking Disclaimer: Actual results may differ materially due to known and unknown risks, and the company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the status of regulatory approvals, specifically under the Hart-Scott-Rodino Act, required for the 2023 closing.
- Monitor the achievement of the regulatory and commercial milestones between 2024 and 2028 that could trigger the additional $300 million payment.
- Review future quarterly earnings reports for the anticipated $20 million quarterly charges under "Other (loss) income, net."
- Assess the impact of the $200 million cash contribution on DaVita's liquidity and stock repurchase program.
- Confirm the governance structure of NewCo, specifically the composition of the six-person board of directors.